{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T01:35:20Z","timestamp":1762047320559,"version":"build-2065373602"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T00:00:00Z","timestamp":1647820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Increases in resistance to fluoroquinolones have been correlated with the use of levofloxacin in the treatment of infections caused by <jats:italic>Escherichia coli.<\/jats:italic> The analysis presents the in vitro activity of ceftazidime-avibactam and comparator agents against 10,840 levofloxacin-resistant <jats:italic>E. coli<\/jats:italic> isolates collected from four geographic regions (Africa\/Middle East, Europe, Asia\/South Pacific, Latin America) between 2012 and 2018.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Non-duplicate clinical isolates of <jats:italic>E. coli<\/jats:italic> were collected from participating centres and shipped to IHMA, Inc., (Schaumburg, IL, USA). Susceptibility testing was performed with frozen broth microdilution panels manufactured by IHMA, according to CLSI guidelines. Levofloxacin-resistance was defined at a minimum inhibitory concentration of\u2009\u2265\u20092\u00a0mg\/L. Isolates collected between 2012 and 2015 were tested for extended-spectrum \u03b2-lactamase (ESBL) activity by determining susceptibility to cefotaxime, cefotaxime-clavulanate, ceftazidime, and ceftazidime-clavulanate as recommended by CLSI guidelines. Isolates collected between 2016 and 2018 were identified as ESBL-positive by genotype using multiplex polymerase chain reaction assays.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 74.8% of levofloxacin-resistant <jats:italic>E. coli<\/jats:italic> isolates in the analysis were from three culture sources: urinary tract infections (N\u2009=\u20093229; 29.8%), skin and skin structure infections (N\u2009=\u20092564; 23.7%) and intra-abdominal infections (N\u2009=\u20092313; 21.3%). Susceptibility rates to ceftazidime-avibactam were consistently high in all regions against both ESBL-positive (97.0% in Asia\/South Pacific to 99.7% in Africa\/Middle East and Latin America) and ESBL-negative isolates (99.4% in Asia\/South Pacific to 100% in Latin America). Susceptibility was also high in each region among ESBL-positive and ESBL-negative isolates to colistin (\u2265\u200998.5%), imipenem (\u2265\u200996.5%), meropenem (\u2265\u200996.5%) and tigecycline (\u2265\u200994.1%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Antimicrobial susceptibility to ceftazidime-avibactam among levofloxacin-resistant <jats:italic>E. coli<\/jats:italic> isolates, including ESBL-positive isolates, collected from four geographical regions between 2012 and 2018 was consistently high. Susceptibility to the comparator agents colistin, tigecycline, imipenem and meropenem was also high.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12941-022-00504-8","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T16:02:43Z","timestamp":1647878563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Antimicrobial activity of ceftazidime-avibactam and comparators against levofloxacin-resistant Escherichia coli collected from four geographic regions, 2012\u20132018"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6115-2567","authenticated-orcid":false,"given":"Gregory G.","family":"Stone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith A.","family":"Hackel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,3,21]]},"reference":[{"key":"504_CR1","unstructured":"World Health Organization (WHO). Antimicrobial resistance. Global action plan on antimicrobial resistance. Geneva: WHO; 2015. http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/193736\/9789241509763_eng.pdf. Accessed 15 Sept 2020."},{"issue":"Suppl 2","key":"504_CR2","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1111\/j.1469-0691.1998.tb00692.x","volume":"4","author":"G Drusano","year":"1998","unstructured":"Drusano G, Labro M-T, Cars O, Mendes P, Shah P, S\u00f6rgel F, et al. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Microbiol Infect. 1998;4(Suppl 2):S27\u201341.","journal-title":"Clin Microbiol Infect"},{"key":"504_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.jmii.2011.12.019","volume":"49","author":"H-H Wu","year":"2016","unstructured":"Wu H-H, Liu H-Y, Lin Y-C, Hsueh P-R, Lee Y-J. Correlation between levofloxacin consumption and the incidence of nosocomial infections due to fluoroquinolone-resistant Escherichia coli. J Microbiol Immunol Infect. 2016;49:424\u20139.","journal-title":"J Microbiol Immunol Infect"},{"issue":"Suppl 1","key":"504_CR4","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1086\/514923","volume":"27","author":"DC Hooper","year":"1998","unstructured":"Hooper DC. Bacterial topoisomerases, anti-topoisomerases, and anti-topoisomerase resistance. Clin Infect Dis. 1998;27(Suppl 1):S54-63.","journal-title":"Clin Infect Dis"},{"key":"504_CR5","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/nyas.12830","volume":"1354","author":"DC Hooper","year":"2015","unstructured":"Hooper DC, Jacoby GA. Mechanisms of drug resistance: quinolone resistance. Ann N Y Acad Sci. 2015;1354:12\u201331.","journal-title":"Ann N Y Acad Sci"},{"key":"504_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jmii.2011.01.015","volume":"44","author":"P-R Hsueh","year":"2011","unstructured":"Hsueh P-R, Lau Y-J, Ko W-C, Liu C-Y, Huang C-T, Yen M-Y, et al. Consensus statement on the role of fluoroquinolones in the management of urinary tract infections. J Microbiol Immunol Infect. 2011;44:79\u201382.","journal-title":"J Microbiol Immunol Infect"},{"key":"504_CR7","unstructured":"European Centre for Disease Prevention and Control. Antimicrobial resistance in the EU\/EEA (EARS-Net)\u2014Annual Epidemiological Report 2019. Stockholm: ECDC; 2020."},{"issue":"Suppl 1","key":"504_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/jtm\/taw102","volume":"24","author":"Y Doi","year":"2017","unstructured":"Doi Y, Lovleva A, Bonomo RA. The ecology of extended-spectrum beta-lactamases (ESBLs) in the developed world. J Travel Med. 2017;24(Suppl 1):44\u201351.","journal-title":"J Travel Med"},{"key":"504_CR9","doi-asserted-by":"publisher","first-page":"5694","DOI":"10.1073\/pnas.1322678111","volume":"111","author":"NK Petty","year":"2014","unstructured":"Petty NK, Ben Zakour NL, Stanton-Cook M, Skippington E, Totsika M, Forde BM, et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci USA. 2014;111:5694\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"504_CR10","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/infdis\/jis933","volume":"207","author":"JR Johnson","year":"2013","unstructured":"Johnson JR, Tchesnokova V, Johnston B, Clabots C, Roberts PL, Billig M, et al. Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis. 2013;207:919\u201328.","journal-title":"J Infect Dis"},{"key":"504_CR11","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1128\/CMR.00023-13","volume":"26","author":"PL Woerther","year":"2013","unstructured":"Woerther PL, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of extended-spectrum \u03b2-lactamases in the community: toward the globalization of CTX-M. Clin Microbiol Rev. 2013;26:744\u201358.","journal-title":"Clin Microbiol Rev"},{"key":"504_CR12","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41579-019-0159-8","volume":"17","author":"K Bush","year":"2019","unstructured":"Bush K, Bradford PA. Interplay between \u03b2-lactamases and new \u03b2-lactamase inhibitors. Nat Rev Microbiol. 2019;17:295\u2013306.","journal-title":"Nat Rev Microbiol"},{"key":"504_CR13","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1073\/pnas.1205073109","volume":"109","author":"DE Ehmann","year":"2012","unstructured":"Ehmann DE, Jahic H, Ross PL, Gu R-F, Hu J, Kern G, et al. Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor. Proc Natl Acad Sci USA. 2012;109:11663\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"504_CR14","doi-asserted-by":"publisher","first-page":"e00592","DOI":"10.1128\/AAC.00592-18","volume":"62","author":"KM Kazmierczak","year":"2018","unstructured":"Kazmierczak KM, Bradford PA, Stone GG, de Jonge BLM, Sahm DF. In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-carrying Enterobacteriaceae isolated as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program from 2012 to 2015. Antimicrob Agents Chemother. 2018;62:e00592-e618.","journal-title":"Antimicrob Agents Chemother"},{"key":"504_CR15","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1128\/AAC.04218-14","volume":"59","author":"P Levasseur","year":"2015","unstructured":"Levasseur P, Girard A-M, Miossec C, Pace J, Coleman K. In vitro antibacterial activity of the ceftazidime-avibactam combination against Enterobacteriaceae, including strains with well-characterized \u03b2-lactamases. Antimicrob Agents Chemother. 2015;59:1931\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"504_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.diagmicrobio.2015.02.003","volume":"82","author":"KM Papp-Wallace","year":"2015","unstructured":"Papp-Wallace KM, Bajaksouzian S, Abdelhamed AM, Foster AN, Winkler ML, Gatta JA, et al. Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single \u03b2-lactamases. Diagn Microbiol Infect Dis. 2015;82:65\u20139.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"504_CR17","unstructured":"ATLAS (Antimicrobial Testing Leadership and Surveillance). Pfizer. https:\/\/atlas-surveillance.com. Accessed 15 September 2020."},{"key":"504_CR18","unstructured":"Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically\u2014Tenth Edition: Approved Standard M7-A10. Clinical and Laboratory Standards Institute. 2015. Wayne, PA."},{"key":"504_CR19","unstructured":"International Standards Organization. Clinical laboratory testing and in vitro diagnostic test systems\u2014susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices. Part 1: Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. 2006. ISO 20776\u20131."},{"key":"504_CR20","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, Twenty-sixth informational supplement. CLSI document M100-S26. Clinical and Laboratory Standards Institute. 2016. Wayne, PA."},{"key":"504_CR21","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0. 2020. http:\/\/www.eucast.org. Accessed 21 May 2020."},{"key":"504_CR22","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1128\/AAC.05186-14","volume":"59","author":"SH Lob","year":"2015","unstructured":"Lob SH, Kazmierczak KM, Badal RE, Hackel MA, Bouchillon SK, Biedenbach DJ, et al. Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART Program, 2009 to 2013. Antimicrob Agents Chemother. 2015;59:3606\u201310.","journal-title":"Antimicrob Agents Chemother"},{"key":"504_CR23","doi-asserted-by":"publisher","first-page":"e00862","DOI":"10.1128\/AAC.00862-20","volume":"64","author":"AE Stapleton","year":"2020","unstructured":"Stapleton AE, Wagenlehner FME, Mulgirigama A, Twynholm M. Escherichia coli resistance to fluoroquinolones in community-acquired uncomplicated urinary tract infection in women: a systematic review. Antimicrob Agents Chemother. 2020;64:e00862-e920.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"504_CR24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1128\/CMR.00125-13","volume":"27","author":"M-H Nicolas-Chanoine","year":"2014","unstructured":"Nicolas-Chanoine M-H, Bertrand X, Madec J-Y. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev. 2014;27(3):543\u201374.","journal-title":"Clin Microbiol Rev"},{"key":"504_CR25","doi-asserted-by":"publisher","first-page":"4997","DOI":"10.1128\/AAC.02824-14","volume":"58","author":"R Banerjee","year":"2014","unstructured":"Banerjee R, Johnson JR. A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131. Antimicrob Agents Chemother. 2014;58:4997\u20135004.","journal-title":"Antimicrob Agents Chemother"},{"key":"504_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2020.115034","volume":"97","author":"BD Johnston","year":"2020","unstructured":"Johnston BD, Thuras PD, Johnson JR. Activity of ceftazidime-avibactam against Escherichia coli isolates from US veterans (2011) in relation to co-resistance and sequence type 131 (ST131) H30 and H30Rx status. Diagn Microbiol Infect Dis. 2020;97:115034.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"504_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12941-020-00355-1","volume":"19","author":"W-C Ko","year":"2020","unstructured":"Ko W-C, Stone GG. In vitro activity of ceftazidime\u2013avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015\u20132017). Ann Clin Microbiol Antimicrob. 2020;19:14.","journal-title":"Ann Clin Microbiol Antimicrob"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-022-00504-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-022-00504-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-022-00504-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T16:03:34Z","timestamp":1647878614000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-022-00504-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,21]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["504"],"URL":"https:\/\/doi.org\/10.1186\/s12941-022-00504-8","relation":{},"ISSN":["1476-0711"],"issn-type":[{"type":"electronic","value":"1476-0711"}],"subject":[],"published":{"date-parts":[[2022,3,21]]},"assertion":[{"value":"26 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As the ATLAS program does not require any additional tests, expenses, or procedures on behalf of the patient outside of normal patient care and no patient identifiers are collected ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Each participating Investigator\/Institution was required to sign a participation agreement that gave explicit rights allowing the submitted organisms to be included in ATLAS and confirming acceptance that the data may be used for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GGS is an employee of Pfizer Inc. and a Pfizer Inc. shareholder. MAH is an employee of IHMA and has no personal financial interests in the sponsor of the study (Pfizer, Inc.).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}